Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Vanguard International High Dividend Yield ETF — how do they compare? Vertex Pharmaceuticals Incorporated trades at $529.5 (market cap $132.79B), while Vanguard International High Dividend Yield ETF trades at $104.45. Which is the better fit depends on your goals.
| VRTX | VYMI | |
|---|---|---|
Market Cap | $132.79B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $529.65 | $105.05 |
52-Week Low | $376.62 | $82.92 |
Enterprise Value | $126.92B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
VYMI trades at $105.05, up 0.64% on the day, near its 52-week high with a bullish technical signal. The ETF offers a 3.4% dividend yield and has delivered strong returns, outperforming the S&P 500 with a 55% total return since last coverage. Recent institutional buying and positive media coverage highlight growing investor interest in its international high-dividend strategy.
Outlook remains positive due to diversification benefits and dividend growth, but risks include currency fluctuations and global economic volatility. Analysts favor its yield and growth potential, though overbought RSI levels suggest near-term consolidation may occur.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
